ZIVO — Zivo Bioscience Share Price
0.000.00%
Last trade - 00:00- $22.50m
- $22.46m
- $0.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 813.7 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -26267.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.02 | n/a | n/a | 0.03 | 0.55 | 1.51 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zivo Bioscience, Inc. is a research and development company. The Company operates in both the biotech and agtech sectors, with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Its product candidates are at different stages of development for different applications. It is developing a product candidate targeting poultry gut health. It is developing products for Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Algal biomass for human consumption, and Biomass for supporting skin health/anti-aging. It is focused on licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement, and medical food manufacturers.
Directors
- John Payne CHM (74)
- Keith Marchiando CFO (58)
- Alison Cornell DRC (58)
- Christopher Maggiore IND (55)
- Nola Masterson IND (74)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 28th, 1983
- Public Since
- October 6th, 2000
- No. of Shareholders
- 209
- No. of Employees
- 8
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 2,777,639
- Address
- 21 E. Long Lake Road, Suite 100, BLOOMFIELD HILLS, 48304
- Web
- https://zivobioscience.com/
- Phone
- +1 2484529866
- Contact
- Tirth Patel
- Auditors
- BDO USA, P.C.
Upcoming Events for ZIVO
Zivo Bioscience Inc Annual Shareholders Meeting
Zivo Bioscience Inc Annual Shareholders Meeting
Q2 2024 Zivo Bioscience Inc Earnings Release
Similar to ZIVO
Adia Nutrition
Pink Sheets on Nasdaq
Agri-Dynamics
Pink Sheets on Nasdaq
Agristar
Pink Sheets on Nasdaq
Aifarm
Pink Sheets on Nasdaq
AiXin Life International
Pink Sheets on Nasdaq
FAQ
What is the Zivo Bioscience share price?
As of Today at 01:25 UTC, shares in Zivo Bioscience are trading at $8.10. This share price information is delayed by 15 minutes.
How has the Zivo Bioscience share price performed this year?
Shares in Zivo Bioscience last closed at $8.10 and the price had moved by -53.13% over the past 365 days. In terms of relative price strength the Zivo Bioscience share price has underperformed the S&P500 Index by -59.51% over the past year.
What are the analyst and broker recommendations for Zivo Bioscience?
The overall consensus recommendation for Zivo Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Zivo Bioscience dividend yield?
Zivo Bioscience does not currently pay a dividend.
Does Zivo Bioscience pay a dividend?
Zivo Bioscience does not currently pay a dividend.
When does Zivo Bioscience next pay dividends?
Zivo Bioscience does not currently pay a dividend.
How do I buy Zivo Bioscience shares?
To buy shares in Zivo Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zivo Bioscience?
As of the previous close price of $8.10, shares in Zivo Bioscience had a market capitalisation of $22.50m.
Where are Zivo Bioscience shares listed?
Here are the trading details for Zivo Bioscience:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ZIVO
What kind of share is Zivo Bioscience?
Based on an overall assessment of its quality, value and momentum Zivo Bioscience is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zivo Bioscience share price forecast for 2024?
The analyst consensus target price for shares in Zivo Bioscience is $12.00. That is 48.15% above the last closing price of $8.10.
Analysts covering Zivo Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -$2.76 for the next financial year.
What is the trend in the Zivo Bioscience share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zivo Bioscience. Over the past six months, its share price has outperformed the S&P500 Index by +155.04%.
As of the last closing price of $8.10, shares in Zivo Bioscience were trading +11.51% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zivo Bioscience PE Ratio?
The Zivo Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zivo Bioscience?
Zivo Bioscience's management team is headed by:
- John Payne - CHM
- Keith Marchiando - CFO
- Alison Cornell - DRC
- Christopher Maggiore - IND
- Nola Masterson - IND